Spoken Alpha
Bone Biologics Corp
Bone Biologics develops NB1, a bone graft device combining recombinant human protein NELL-1 with demineralized bone matrix for spinal fusion surgery. The company is in clinical-stage development, currently conducting a pilot study in Australia to evaluate safety and effectiveness in patients with degenerative disc disease undergoing lumbar spinal fusion.
Bone Biologics Corp is a Healthcare company operating in Biotechnology with a $1.5M market cap.
BBLG missed consensus EPS by 0.1% in Q2 FY2026, reported Aug 13, 2026.
Behavioral analysis
Disclosures
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add BBLG, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BBLG.
$ curl https://api.spokenalpha.com/v1/companies/BBLGFAQ
Spoken Alpha indexes BBLG's earnings call transcripts at https://spokenalpha.com/companies/BBLG. Each call links to attributed speakers and parsed analyst Q&A.
Bone Biologics Corp (BBLG) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-0.43 | $-0.39 | -10.3% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-03-30 | $-0.43 | $-0.54 | +20.4% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-01 | $-0.63 | $-0.34 | -85.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.37 | $-1.23 | +69.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-1.33 | $-0.58 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.32 | $-7.68 | +95.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-2.88 | $-3.90 | +26.2% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-14.22 | $-3.60 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-4.02 | $-8.34 | +51.8% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-7.86 | $-45.60 | +82.8% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-19 | $-2.47 | $-5.60 | +55.9% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-29.28 | $-145.92 | +79.9% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-81.12 | $-72.00 | -12.7% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-331.20 | $-100.80 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.18 | $-0.22 | +18.2% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-172.80 | $-216.00 | +20.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-72.00 | $-172.80 | +58.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-100.80 | $-288.00 | +65.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-14 | $-0.05 | $-0.17 | +70.6% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-15 | $-0.17 | $-0.17 | 0.0% | $0 | — | — | EODHD |
Source: EODHD. BBLG reported actuals as published; sparse fields render as —.